A descriptive study of vitamin D and other nutritional factors in breast cancer patients in Saudi Arabia

Background Deficiency of vitamin-D (Vit-D) was associated with poor survival outcome in several studies across different tumour types. The present study aims to assess the prevalence and prognostic value of Vit-D deficiency among breast cancer patients in a single institution in Saudi Arabia. Methods In this retrospective study, we screened patients who presented with non-metastatic breast cancer to King Abdullah Medical City, Saudi Arabia from June 2011 to December 2015. We checked baseline Vit-D level before starting systemic therapy in addition to other clinicopathological factors. Low Vit-D was defined as Vit-D level less than 30 ng /ml. The relations of Vit-D level (taking the median as the cutoff) with clinicopathological factors were assessed using Chi-Square test. Differences in survival outcome were compared using log rank test. Results We screened 340 patients with non-metastatic breast cancer. Baseline Vit-D levels were available for 189 patients. The median age was 50 years (range: 26- 86 years). Noteworthy, 169 (89.4%) of patients had Vit-D level <30 ng/ml with a median of 14.9 ng/ml (range: 4.0 - 45.0). Low Vit-D level (below the median) was significantly more common in premenopausal (p=0.011) and ER-negative patients (p=0.011). However, lymphovascular invasion (p=0.001), clinically (p=0.023) and pathologically positive axillary LNs (p=0.041) were linked with higher Vit- D level. After a median follow up period of 58.2 months, 14 patients died and 40 relapsed. The 5-year disease-free survival (DFS) rates was 74.8%. The 5-year DFS rate in patients with higher Vit-D level above the median was 78.8% compared to 71.1% in patients with lower Vit-D level with no statistically significance difference (p= 0.22). The 5-year overall survival (OS) rate was 90.2%. Meanwhile, no difference in 5-year OS rate in patients with higher and lower Vit-D levels (90.3% and 89.7% respectively, p=0.6). Conclusion Low Vit-D level was prevalent among the studied breast cancer patients. Low Vit-D level was associated with ER-negative phenotype and premenopausal patients. Baseline Vit-D level was not significantly linked with survival outcome.

Download Full-text

90P Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia

Annals of Oncology ◽

10.1016/s0923-7534(21)00250-7 ◽

2016 ◽

Vol 27 ◽

pp. ix26

Author(s):

S. Elsamany ◽

A. Alzahrani ◽

O. Elemam ◽

S. Elmorsy ◽

N. Abo Hashish

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Saudi Arabia ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Metastatic Breast ◽

Breast Cancer Patients

Download Full-text

90P Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia

Annals of Oncology ◽

10.1093/annonc/mdw575.029 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

S. Elsamany ◽

A. Alzahrani ◽

O. Elemam ◽

S. Elmorsy ◽

N. Abo Hashish

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Saudi Arabia ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Metastatic Breast ◽

Breast Cancer Patients

Download Full-text

Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia.

Asian Pacific Journal of Cancer Care ◽

10.31557/apjcc.2020.5.1.9-14 ◽

2020 ◽

Vol 5 (1) ◽

pp. 9-14

Author(s):

Shereef Elsamany ◽

Omaima Elemam ◽

Ahmed Zeeneldin ◽

Soha Elmorsy ◽

Ahmed Khatry ◽

...

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Saudi Arabia ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Metastatic Breast ◽

Survival Outcome ◽

Clinicopathological Factors ◽

Breast Cancer Patients

Background Deficiency of vitamin-D (Vit-D) was associated with poor survival outcome in several studies across different tumour types. The present study aims to assess the prevalence and prognostic value of Vit-D deficiency among breast cancer patients in a single institution in Saudi Arabia. Methods In this retrospective study, we screened patients who presented with non-metastatic breast cancer to King Abdullah Medical City, Saudi Arabia from June 2011 to December 2015. We checked baseline Vit-D level before starting systemic therapy in addition to other clinicopathological factors. Low Vit-D was defined as Vit-D level less than 30 ng /ml. The relations of Vit-D level (taking the median as the cutoff) with clinicopathological factors were assessed using Chi-Square test. Differences in survival outcome were compared using log rank test. Results We screened 340 patients with non-metastatic breast cancer. Baseline Vit-D levels were available for 189 patients. The median age was 50 years (range: 26- 86 years). Noteworthy, 169 (89.4%) of patients had Vit-D level <30 ng/ml with a median of 14.9 ng/ml (range: 4.0 - 45.0). Low Vit-D level (below the median) was significantly more common in premenopausal (p=0.011) and ER-negative patients (p=0.011). However, lymphovascular invasion (p=0.001), clinically (p=0.023) and pathologically positive axillary LNs (p=0.041) were linked with higher Vit- D level. After a median follow up period of 58.2 months, 14 patients died and 40 relapsed. The 5-year disease-free survival (DFS) rates was 74.8%. The 5-year DFS rate in patients with higher Vit-D level above the median was 78.8% compared to 71.1% in patients with lower Vit-D level with no statistically significance difference (p= 0.22). The 5-year overall survival (OS) rate was 90.2%. Meanwhile, no difference in 5-year OS rate in patients with higher and lower Vit-D levels (90.3% and 89.7% respectively, p=0.6). Conclusion Low Vit-D level was prevalent among the studied breast cancer patients. Low Vit-D level was associated with ER-negative phenotype and premenopausal patients. Baseline Vit-D level was not significantly linked with survival outcome.

Download Full-text

Low Calcium, Vitamin D Intake Rampant in Breast Cancer Patients

Internal Medicine News ◽

10.1016/s1553-3212(05)70340-x ◽

2005 ◽

Vol 38 (5) ◽

pp. 48

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Vitamin D Intake ◽

Low Calcium

Download Full-text

Vitamin D receptor status of circulating tumor cells (CTC) in metastatic breast cancer patients

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592738 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

X Zhang ◽

S Hofmann ◽

B Rack ◽

N Harbeck ◽

U Jeschke ◽

...

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Vitamin D Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Receptor Status

Download Full-text

Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies

Integrative Cancer Therapies ◽

10.1177/1534735417712007 ◽

2017 ◽

Vol 17 (2) ◽

pp. 217-225 ◽

Cited By ~ 20

Author(s):

Kejia Hu ◽

David Frederick Callen ◽

Jiayuan Li ◽

Hong Zheng

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Overall Survival ◽

Cancer Patients ◽

Dose Response ◽

Fixed Effects ◽

Meta Analysis ◽

Breast Cancer Patients ◽

Fixed Effects Model ◽

Vitamin D Levels

Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients’ vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies. Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model. A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships. Six studies with a total number of 5984 patients were identified. A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), Pfor linear trend < .001. At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively. There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels. Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer. However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.

Download Full-text